[Glycine therapy of schizophrenia; its rationale and a review of clinical trials].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Semba J;Semba J
  • Source:
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology [Nihon Shinkei Seishin Yakurigaku Zasshi] 1998 Jun; Vol. 18 (3), pp. 71-80.
  • Publication Type:
    English Abstract; Journal Article; Review
  • Language:
    Japanese
  • Additional Information
    • Source:
      Publisher: Nihon Shinkei Seishin Yakuri Gakkai Country of Publication: Japan NLM ID: 9509023 Publication Model: Print Cited Medium: Print ISSN: 1340-2544 (Print) Linking ISSN: 13402544 NLM ISO Abbreviation: Nihon Shinkei Seishin Yakurigaku Zasshi Subsets: MEDLINE
    • Publication Information:
      Original Publication: Kawasaki-shi : Nihon Shinkei Seishin Yakuri Gakkai, 1994-2017.
    • Subject Terms:
      Amino Acid Transport Systems, Neutral*; Glycine/*therapeutic use ; Schizophrenia/*drug therapy; Acetamides/therapeutic use ; Alanine/pharmacology ; Alanine/therapeutic use ; Animals ; Carrier Proteins/antagonists & inhibitors ; Cycloserine/therapeutic use ; Glutamic Acid/physiology ; Glycine/analogs & derivatives ; Glycine/pharmacology ; Glycine Plasma Membrane Transport Proteins ; Humans ; Prodrugs/therapeutic use ; Receptors, Glycine/agonists ; Receptors, N-Methyl-D-Aspartate/agonists ; Schizophrenia/etiology ; Serine/pharmacology ; Serine/therapeutic use
    • Abstract:
      A major ground of dopamine hypothesis of schizophrenia is that all antipsychotics share dopamine D2 antagonistic activity. However, they are less effective in ameliorating the negative symptoms of schizophrenia. Recently, glutamate hypothesis of schizophrenia has been developed from the observation that phencyclidine, an NMDA receptor antagonist, induces a psychotic state closely resembling schizophrenia in normal individuals. Because glycine potentiates NMDA receptor activity, it has been tried as an adjunct to conventional antipsychotics. Most trials demonstrated a moderate improvement in negative symptoms. In this review we discussed the clinical usefulness of glycine therapy. First we described glutamate hypothesis of schizophrenia as a theoretical basis of glycine therapy. Then we reviewed clinical trials of glycine or other glycinergic agents (glycine receptor partial agonist, D-cycloserine, or the glycine prodrug milacemide). Although long-term side effects of glycine administration have not been fully investigated, glycine therapy could be a potential therapeutic tool for the negative symptoms of schizophrenia.
    • Number of References:
      63
    • Accession Number:
      0 (Acetamides)
      0 (Amino Acid Transport Systems, Neutral)
      0 (Carrier Proteins)
      0 (Glycine Plasma Membrane Transport Proteins)
      0 (Prodrugs)
      0 (Receptors, Glycine)
      0 (Receptors, N-Methyl-D-Aspartate)
      0 (glycyldodecylamide)
      0HXT24RECU (milacemide)
      3KX376GY7L (Glutamic Acid)
      452VLY9402 (Serine)
      95IK5KI84Z (Cycloserine)
      OF5P57N2ZX (Alanine)
      TE7660XO1C (Glycine)
    • Publication Date:
      Date Created: 19981104 Date Completed: 19990210 Latest Revision: 20131121
    • Publication Date:
      20231215
    • Accession Number:
      9800198